New drug aims to scrub sticky proteins from heart muscle

NCT ID NCT07448623

Recruiting now Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tests a drug called coramitug in 14 people with ATTR-CM, a heart condition caused by abnormal protein buildup. The drug is designed to bind to and help remove these protein clumps from the heart. Researchers will use special scans to see where the drug goes and whether it can clear the deposits, while also checking for safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: coramitug (a monoclonal antibody)
What this could lead to: If successful, this could point toward a treatment that removes abnormal protein clumps from the heart in ATTR-CM, potentially slowing or improving the disease.
What could go wrong: This is a very early Phase 1 study with only 14 participants, so it is primarily testing safety and imaging, not effectiveness. The drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

wild type ATTR amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRANSTHYRETIN AMYLOID CARDIOMYOPATHY

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

ICON - location Groningen
RECRUITING

Groningen, 9728 NZ, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.